Flare Therapeutics appoints Daphne Karydas COO and CFO, and Michaela Bowden, PhD, SVP of Biology and Translation



CAMBRIDGE, Mass .– (COMMERCIAL THREAD) – Flare Therapeutics, a biotechnology company targeting transcription factors to discover precision drugs for cancer and other diseases, today announced the appointment of Daphne Karydas as COO and Director Financial, and Michaela Bowden, PhD, as Senior Vice President of Biology and Translation.

“We are delighted to grow the Flare leadership team with the appointment of these two exceptional and accomplished industry leaders, to deepen our expertise in business and science, and to position Flare for growth” said Abbie Celniker, PhD, Interim CEO of Flare. and partner of Third Rock Ventures. “Daphne’s decades of experience in a range of financial leadership roles in the biopharmaceutical industry and her proven skills in developing and executing growth strategies will be invaluable as we evolve Flare and grow as a platform. form of oncology and pipeline company. Michaela brings her own in-depth experience and a set of essential skills to successfully conduct biology and translational research, enabling multidisciplinary R&D strategies to bridge our discovery of cutting-edge oncology drugs to high-impact precision drugs in clinical. ”

Daphne Karydas, COO and CFO

“I couldn’t imagine a more exciting time and opportunity to join Flare,” Ms. Karydas said. “I feel fortunate to have the opportunity to work with such a talented team who are focused on innovating in a radically new way of targeting transcription factors and bringing new drugs to cancer patients in need. . I look forward to using my experience in building and leading finance teams and my operational capabilities to help a growing organization execute its strategy, goals and mission to make an impact on the lives of people. patients.

Daphne Karydas brings to Flare over 20 years of financial and operational experience in the biopharmaceutical industry, most recently as CFO of Syndax Pharmaceuticals (Nasdaq: SNDX.) Previously, she worked at Allergan as Vice President Principal of Corporate Financial Planning and Analysis and Strategy, where she oversaw the company’s long-term financial and business strategy until its acquisition by AbbVie in May 2020, and as Senior Vice President of Global Investor Relations and Strategy. Prior to joining Allergan, she was Executive Director and Senior Healthcare Analyst at JP Morgan Asset Management and Portfolio Manager and Senior Healthcare Analyst at The Boston Company Asset Management, a BNY Mellon company. Previously, Ms. Karydas was Vice President of Goldman Sachs Asset Management, specializing in healthcare, as well as a member of the Goldman Sachs healthcare investment banking team. Prior to joining Goldman Sachs, she was a Project Chemical Engineer at Merck & Co. where she focused on process development for new vaccines. She currently sits on the board of directors of Eucrates Biomedical Acquisition Corp. and LogicBio Therapeutics, each a publicly traded company, and Elicio Therapeutics, a private biotechnology company. Ms. Karydas holds a BA and an MS in Chemical Engineering from the Massachusetts Institute of Technology and an MBA from Harvard Business School.

Michaela Bowden, PhD, Senior Vice President of Biology and Translation

“It is a privilege to join Flare at a time when there is an opportunity to develop and shape our R&D strategies to enable a revolutionary new approach to targeting transcription factors via site switching,” said Dr. Bowden . “Flare’s innovative approach gives us the potential to create very promising precision drugs for cancer, and I look forward to bringing my own unique perspective and R&D expertise to the incredible team at Flare.

Michaela Bowden, PhD, is an accomplished scientist and leader with over 15 years of experience building multidisciplinary research teams in drug discovery organizations of all sizes. Dr Bowden joins Flare from Bristol Myers Squibb (BMS) where she served as Executive Director of Translational Biology and led teams at research sites in Cambridge, Massachusetts and New Jersey focused on drug development in immuno-oncology. Prior to BMS, she held scientific leadership positions at the Dana-Farber Cancer Institute and the Novartis Institutes for Biomedical Research, as well as within a life sciences start-up in her native Ireland. Dr. Bowden has expertise in elucidating patient phenotypes associated with tumor heterogeneity and the tumor microenvironment, which has led her to develop novel biomarker approaches that define high-risk patient segments not satisfied by current treatment regimens. She has technical experience ranging from the development of biotechnology platforms to the exploitation of cutting-edge disruptive technologies to address key translational hypotheses that impact drug discovery, creating a large network of collaboration across a diverse network. experts in oncology at the intersection of clinical, biopharmacy and biotechnology. . Dr Bowden was a postdoctoral researcher at Tufts University in the areas of test development, multiplexed diagnostics and next-generation sequencing. She holds a BA and a PhD in Analytical Sciences and Microfluidics from Dublin City University.

About Flare Therapeutics

Flare Therapeutics is a biotechnology company that is opening a new therapeutic space with a new approach to decipher the biology of transcription factors in order to develop small molecule drugs. Based on information from the seminal work of its scientific founders, Flare’s team discovered “switch sites,” drug regions that are key targets for the regulation of transcription factors to treat mutations that cause disease. Our discovery of drugs to target switch sites has advanced rapidly, resulting in an emerging pipeline of drug programs that address well-validated transcription factors, initially focused on precision oncology with future potential in neurology, rare genetic disorders. , immunology and inflammation. Flare Therapeutics was launched in 2021 and is backed by founding investor Third Rock Ventures, Boxer Capital, Nextech Invest, Casdin Capital, Invus Financial Advisors and Eventide Asset Management. For more information, please visit www.flaretx.com.

We invite you to follow us on LinkedIn and @Flaretx.


Leave A Reply

Your email address will not be published.